# Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

> **NCT02115282** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 608 (actual)

## Conditions studied

- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Breast Adenocarcinoma
- HER2/Neu Negative
- Locally Advanced Breast Carcinoma
- Metastatic Breast Carcinoma
- Recurrent Breast Carcinoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Entinostat
- **DRUG:** Exemestane
- **DRUG:** Goserelin
- **DRUG:** Goserelin Acetate
- **PROCEDURE:** Magnetic Resonance Imaging
- **OTHER:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT02115282
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-03-29
- **Primary completion:** 2020-05-05
- **Final completion:** 2026-06-02
- **Target enrollment:** 608 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02115282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02115282, "Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02115282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*